CN105188731B - 用于治疗眼部疾病的蛋白质slurp-1 - Google Patents

用于治疗眼部疾病的蛋白质slurp-1 Download PDF

Info

Publication number
CN105188731B
CN105188731B CN201380064175.2A CN201380064175A CN105188731B CN 105188731 B CN105188731 B CN 105188731B CN 201380064175 A CN201380064175 A CN 201380064175A CN 105188731 B CN105188731 B CN 105188731B
Authority
CN
China
Prior art keywords
slurp
group
seq
healing
protein
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN201380064175.2A
Other languages
English (en)
Chinese (zh)
Other versions
CN105188731A (zh
Inventor
让-马克·孔贝特
凯瑟琳·德洛什
克莱尔·阿巴迪
塞巴斯蒂安·穆兹
朱利安·佩里诺
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
BRIGHTPULSE HOLDING Ltd
Original Assignee
BRIGHTPULSE HOLDING Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by BRIGHTPULSE HOLDING Ltd filed Critical BRIGHTPULSE HOLDING Ltd
Publication of CN105188731A publication Critical patent/CN105188731A/zh
Application granted granted Critical
Publication of CN105188731B publication Critical patent/CN105188731B/zh
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Cell Biology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Inorganic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
CN201380064175.2A 2012-12-07 2013-12-09 用于治疗眼部疾病的蛋白质slurp-1 Expired - Fee Related CN105188731B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP12196007.4 2012-12-07
EP12196007.4A EP2740485B1 (en) 2012-12-07 2012-12-07 Protein slurp-1 for use in the treatment of ocular diseases
PCT/EP2013/075981 WO2014087022A1 (en) 2012-12-07 2013-12-09 Protein slurp-1 for use in the treatment of ocular diseases

Publications (2)

Publication Number Publication Date
CN105188731A CN105188731A (zh) 2015-12-23
CN105188731B true CN105188731B (zh) 2019-02-05

Family

ID=47297008

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201380064175.2A Expired - Fee Related CN105188731B (zh) 2012-12-07 2013-12-09 用于治疗眼部疾病的蛋白质slurp-1

Country Status (15)

Country Link
US (1) US10098925B2 (https=)
EP (1) EP2740485B1 (https=)
JP (1) JP6335188B2 (https=)
KR (1) KR20150108351A (https=)
CN (1) CN105188731B (https=)
AU (1) AU2013353957B2 (https=)
BR (1) BR112015013215A2 (https=)
CA (1) CA2891201A1 (https=)
CL (1) CL2015001520A1 (https=)
EA (1) EA201591095A1 (https=)
IL (1) IL239078A0 (https=)
MX (1) MX2015006779A (https=)
SG (2) SG10201705592YA (https=)
WO (1) WO2014087022A1 (https=)
ZA (1) ZA201503747B (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2740485B1 (en) * 2012-12-07 2018-10-31 Brightpulse Holding LTD. Protein slurp-1 for use in the treatment of ocular diseases
EP3689327B1 (fr) * 2019-01-24 2025-03-12 Organes Tissus Régénération Réparation Remplacement Composition pharmaceutique dans le traitement de lésions pulmonaires
CN114601915B (zh) * 2022-03-25 2023-04-07 四川大学华西医院 Slurp1蛋白在制备预防或治疗皮肤弹性纤维疾病的药物中的用途

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994014959A1 (en) * 1992-12-22 1994-07-07 Applied Research Systems Ars Holding N.V. New protein from urine named component b
WO2004091646A3 (en) * 2003-04-16 2004-12-16 Univ Lausanne Use of slurp-1 for treating diseases related to acetylcholine receptors dysfunction
WO2010138379A2 (en) * 2009-05-29 2010-12-02 Allergan, Inc. Methods of treating chronic neurogenic inflammation using galanin retargeted endopeptidases

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2806143A1 (en) * 2010-07-30 2012-02-02 Biopharm Gesellschaft Zur Biotechnologischen Entwicklung Von Pharmaka Mb H Drug delivery devices and growth factor formulations for accelerated wound healing
EP3848055A1 (en) * 2011-06-03 2021-07-14 Ophidion Inc. Compositions and methods for transport across the blood brain barrier
US9132193B2 (en) * 2012-11-05 2015-09-15 University of Pittsburgh—of the Commonwealth System of Higher Education Use of Slurp1 as an imunomodulatory molecule in the ocular surface
CA2890424C (en) * 2012-11-08 2020-11-17 Yamaguchi University Therapeutic agent for keratoconjunctive disorders
EP2740485B1 (en) * 2012-12-07 2018-10-31 Brightpulse Holding LTD. Protein slurp-1 for use in the treatment of ocular diseases

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994014959A1 (en) * 1992-12-22 1994-07-07 Applied Research Systems Ars Holding N.V. New protein from urine named component b
WO2004091646A3 (en) * 2003-04-16 2004-12-16 Univ Lausanne Use of slurp-1 for treating diseases related to acetylcholine receptors dysfunction
WO2010138379A2 (en) * 2009-05-29 2010-12-02 Allergan, Inc. Methods of treating chronic neurogenic inflammation using galanin retargeted endopeptidases

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Identification of SLURP-1 as an epidermal neuromodulator explains the clinical phenotype of Mal de Meleda;Fabrice Chimienti等;《Human Molecular Genetics》;20031231;第12卷(第22期);3017-3024 *
Novel cholinergic peptides SLURP-1 and -2 regulate epithelialization of cutaneous and oral wounds;Alexander I. Chernyavsky等;《Wound Repair Regen.》;20120131;第20卷(第1期);103-113 *

Also Published As

Publication number Publication date
IL239078A0 (en) 2015-07-30
EP2740485A1 (en) 2014-06-11
SG11201503658XA (en) 2015-06-29
SG10201705592YA (en) 2017-08-30
BR112015013215A2 (pt) 2018-02-06
CN105188731A (zh) 2015-12-23
CA2891201A1 (en) 2014-06-12
EP2740485B1 (en) 2018-10-31
ZA201503747B (en) 2016-03-30
AU2013353957A1 (en) 2015-05-28
CL2015001520A1 (es) 2016-05-20
US20150320831A1 (en) 2015-11-12
JP2016502558A (ja) 2016-01-28
EA201591095A1 (ru) 2015-11-30
KR20150108351A (ko) 2015-09-25
AU2013353957B2 (en) 2018-05-17
WO2014087022A1 (en) 2014-06-12
MX2015006779A (es) 2015-10-29
US10098925B2 (en) 2018-10-16
JP6335188B2 (ja) 2018-05-30

Similar Documents

Publication Publication Date Title
Handa et al. Increase in the advanced glycation end product pentosidine in Bruch's membrane with age.
JP6247692B2 (ja) 皮膚瘢痕を治療する組成物及び方法
JP5894364B2 (ja) 眼および付属器組織の炎症を処置するための治療組成物
Kandarakis et al. The effect of epidermal growth factor on epithelial healing after penetrating keratoplasty in human eyes
TW201615187A (zh) 用於舒緩及減輕近視之醫藥組合物及其製備方法與用途
JP2011516400A5 (https=)
EP1858533A2 (en) Use of amniotic fluid (af) in treating ocular disease and injury
US20240277797A1 (en) Method for treating or preventing neovascular eye disease
JP7026050B2 (ja) 慢性創傷を治療するための組成物及び方法
Yan et al. Smart coating by thermo-sensitive Pluronic F-127 for enhanced corneal healing via delivery of biological macromolecule progranulin
CN105188731B (zh) 用于治疗眼部疾病的蛋白质slurp-1
US5145680A (en) Eye drop formulation useful for treating lesions of corneal epithelium
CN111150831B (zh) 多肽KdPT的应用
JP2009542609A (ja) 薬剤
Bersano et al. Terbinafine in acrylic polymer for the treatment of onychomycosis in hemodialysis patients: a phase II clinical trial
CN109789182A (zh) 治疗干眼综合征的方法
RU2699206C1 (ru) Способ лечения дефектов роговицы с помощью аутологичного тромбофибринового сгустка
Mohamed et al. Vitiligo: Highlights on Pathogenesis, Clinical Presentation and Treatment
Elkhawaga et al. Assessment of Corneal Epithelial Healing Rate after Pterygium Excision When Using 2% Hyaluronic Acid.
CN119837998A (zh) Fgf10在制备治疗低钠血症的药物中的应用
CN111346217B (zh) 多肽tdl23的新用途
US20240016893A1 (en) Compositions and methods for treating wounds
Shilpa A One-Year Prospective Study To Evaluate The Efficacy Of Intraoperative Application Of 20% Ethanol As An Adjuvant In Pterygium Excision With Conjunctival Autograft
To et al. 12. New and upcoming MIGS
CN118924878A (zh) 一种鞘脂激活蛋白原psap作为制备具有抑制新生血管与神经保护作用的治疗眼底疾病药物的应用

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant
CF01 Termination of patent right due to non-payment of annual fee
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20190205

Termination date: 20191209